INTRODUCTION 40
A single dose regimen of azithromycin extended-release (ER) oral suspension (Zmax  ) has been 41 developed to deliver systemic exposure that is comparable to the cumulative exposure observed 42 with the currently approved multiple oral dose regimens of the immediate-release (IR) 43 formulation (5, 16). The ER formulation releases the drug more slowly and in the lower 44 gastrointestinal (GI) tract than conventional IR formulations, thereby reducing GI side effects 45 such as nausea and vomiting. Since the ER formulation partially bypasses the absorption window 46 (upper GI tract), the oral bioavailability of azithromycin ER was compromised to a certain 47 extent. Therefore, higher numeric dose was selected for the ER formation to ensure sufficient 48 azithromycin systemic exposure could be achieved. The 2 g azithromycin ER single dose 49 regimen has been approved worldwide for the treatment of acute bacterial sinusitis and 50 community acquired pneumonia (CAP) in adults. 51
The pharmacokinetics of azithromycin ER have been characterized in pediatric patients aged 3 52 months to 16 years following a 60 mg/kg (maximum of 2 g) azithromycin ER single dose (16) . 53
Although there was large inter-subject variability in systemic exposure (AUC and C max ) across 54 the age groups studied, individual azithromycin AUC and C max values in pediatric subjects were 55 comparable to or higher than those in adults following a 2 g single dose of azithromycin ER. 56
Acute otitis media (AOM) is an important health problem in children. The currently approved 57 azithromycin IR oral suspension for AOM is 30 mg/kg total dose given as a single dose, or given 58 over 3 or 5 days (7, 11, 13, 15) . It has been demonstrated that the 30 mg/kg azithromycin IR 59 single dose regimen was as effective as the 10-day regimen of high dose amoxicillin-clavulanate 60 (90/6.4 mg/kg/day, given in divided doses q12h) for the treatment of AOM in children, whereas 61 rates of AEs were lower and compliance was improved with the single dose regimen (2). 62 on July 7, 2017 by guest http://aac.asm.org/
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Patients 86
Male or female children aged 6 months to 6 years old, inclusive, with clinical signs/symptoms of 87 AOM in at least one ear were included in the study. The clinical signs/symptoms of AOM were 88 defined as follows: (i) Purulent otorrhea of ≤24 hours duration, OR (ii) at least 2 otoscopic signs 89 of middle ear effusion [i.e., decreased or absent tympanic membrane mobility by pneumatic 90 otoscopy, yellow or white discoloration of tympanic membrane, and opacification of tympanic 91 membrane (other than scarring)], AND (iii) at least 1 indicator of acute inflammation to support 92 the diagnosis of AOM (i.e., ear pain, including unaccustomed tugging or rubbing, marked 93 redness of tympanic membrane, and distinct fullness or bulging of tympanic membrane). 94
Subjects were excluded if they had known or suspected hypersensitivity, or intolerance to 95 azithromycin or other macrolides or to any penicillin, beta-lactam antibiotic or beta lactamase 96 inhibitor. Subjects were excluded if they were unable to take oral medications or any condition 97 possibly affecting drug absorption. Subjects were excluded if they had used prescription or 98 nonprescription drugs and dietary supplements, or consumed grapefruit (including grapefruit 99 containing products) within 7 days or 5 half-lives (whichever was longer) prior to the study dosing. As 100 an exception, analgesics such as ibuprofen, acetaminophen could have been used. Other antibiotics 101 without drug-drug interaction with azithromycin were also allowed, such as amoxicillin and 102 cephalosporins. Subjects were excluded if they had any medical condition that could have interfered 103
with the evaluation of the study drug and/or would have made the subject unsuitable for enrollment 104 (eg, tympanostomy tubes in place, otitis externa, evidence of chronic middle ear disease, or 105 perforations of the tympanic membrane in the affected ear for >24 hours prior to study entry). Subjects 106 were also excluded if they had any other condition which, in the opinion of the investigator, made the 107 subject unsuitable for enrollment. 108 on July 7, 2017 by guest http://aac.asm.org/
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Study treatment 109
Each subject received his/her single oral dose of 60 mg/kg ER or 30 mg/kg IR on an empty 110 stomach (1 hour before or 2 hours after a meal). The concentration for azithromycin ER suspension 111 was 27 mg/mL and the concentration for azithromycin IR suspension was 20 mg/mL. Subjects were 112 observed for 1 hour after study drug administration. Any subject who vomited within 1 hour of 113 administration was to receive alternative therapy. Study drug was not to be re-administered to any 114 subject who vomited. used during sample analysis ranged from -1.6% to 3.5% with a precision (as measured by % relative 127 standard deviation) of ≤2.9%. 128
Non-compartmental pharmacokinetic analysis was performed using an internally validated system 129 eNCA v2.2.1. The peak concentration (C max ) and the time to C max (T max ) were estimated directly from 130 the concentration-time profiles. The area under the curve from time zero to 8 hours post-dosing 131 on July 7, 2017 by guest http://aac.asm.org/ Downloaded from (AUC 0-8 ), AUC 0-24 and AUC 0-72 were estimated using the linear/log trapezoidal approximation. Since 132 no pre-dose samples were obtained in order to spare the children an extra blood draw, pre-dose 133 concentrations were assigned a value of zero for AUC calculations. Samples above the limit of 134 quantification were diluted appropriately within the range for assay. Samples below the lower limit of 135 quantification were set to 0 ng/mL for analysis. Actual sample collection times were used for the 136 pharmacokinetic analysis. 137
Safety assessment 138
Adverse events (AEs) were monitored throughout the study. Safety laboratory tests were performed at 139 screening (and day 2 for subjects who were discontinued from the study), and vital signs and physical 140 examinations were performed at screening, prior to dosing on day 1 and at the TOC visit (on days 7 to 141 10). 142
Clinical response assessment 143
At the TOC visit (between days 7 and 10), or when subjects discontinued the study prematurely (if 144 applicable), the investigator assessed the subject's response to therapy according to the following 145 criteria: Cure: clinical signs and symptoms related to the acute illness had resolved, or clinical 146 improvement is such that no additional therapy was necessary. Failure: one or more of the following: 147 (i). signs and symptoms related to the acute illness had persisted or worsened and additional therapy 148 was necessary; (ii). new clinical signs and symptoms of acute illness had developed and additional 149 therapy was necessary. 150
Any worsening of existing signs and symptoms, or new signs and symptoms, were also documented 151 as AEs. 152
Statistical analysis 153
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A sample size of 36 subjects (18 subjects per treatment group) was required to provide 90% 154 power that the lower boundary of the 90% confidence interval (CI) for the ER/IR AUC 0-72 ratio 155 was ≥80%. This estimate was based on the assumption that the true ratio between AUC 0-72 , ER 156 (60 mg/kg) and AUC 0-72 , IR (30 mg/kg) was 1.20 and also assumed inter-subject standard 157 deviations of 0.4 for natural log AUC 0-72 based on historical data (5, 16). 158
One-way analysis of variance (ANOVA) was used to compare natural log transformed AUC 0-8 , 159
AUC 0-24 , AUC 0-72 and C max as well as concentrations at each time point. The 30 mg/kg IR was the 160 reference treatment and the 60 mg/kg ER was the test treatment. The adjusted mean differences (test-161 reference) between treatments and 90% CIs for the differences were exponentiated to provide 162 estimates of the ratio of adjusted geometric means (test/reference) and 90% CIs for the ratios. 163
The criterion for primary comparisons (AUC 0-72 ) between treatments was pre-defined as 164 maintaining at least a lower 90% CI boundary of 80% to demonstrate that the exposure of ER 165 formulation was similar or greater than that of the IR formulation. Other secondary comparisons 166 between treatments were also evaluated using the same criteria. 167
No formal inferential statistics were applied to the safety and clinical response data, and these 168 data were listed for descriptive purpose. 169
RESULTS 170
Subject disposition and demography 171
Thirty-eight (38) children with AOM were enrolled at a single study center in Costa Rica (19 in each 172 treatment group) and 36 of them completed the study. One subject in each treatment group 173 discontinued from the study: in the IR group, one subject was inadvertently given a low dose due 174 to a miscalculation based on weight; while in the ER group, one subject vomited while receiving 175 on July 7, 2017 by guest http://aac.asm.org/ Downloaded from study drug. The two subjects who were discontinued from the study had safety laboratory tests 176 performed on day 2, but were excluded for pharmacokinetic analysis. 177 All subjects were Hispanic. As shown in Table 1 , demographic data were similar between the 178 two treatment groups although the mean age was slightly higher in the IR group (34.5 months) 179 compared with the ER group (24.3 months). 180
Concomitant treatments 181
Seven (7) subjects in the 30 mg/kg azithromycin IR group and four subjects in the 60 mg/kg 182 azithromycin ER group received concomitant mediations during the study, and the most commonly 183 taken concomitant treatment was paracetamol (acetaminophen). Two (2) subjects in the IR group and 184 one subject in the ER group received concomitant antibiotic therapy (i.e., ceftriaxone). 185
Comparison of azithromycin pharmacokinetics between ER and IR 186
Mean azithromycin serum concentration-time profiles for 60 mg/kg ER and 30 mg/kg IR single doses 187 are presented in Figure 1 , and the corresponding pharmacokinetic parameters are summarized in Table  188 2. As expected, the IR single dose regimen had a higher peak concentration and a faster T max 189 compared with the ER single dose regimen since the ER formulation was designed to slow down the 190 absorption rate. As shown in Table 2 , for AUC 0-72 , the ER/IR ratio of the adjusted geometric 191 means was 157.98% with the 90% CI of 98.87% -252.44%. The lower boundary of the 90% CI 192 was greater than the pre-defined criterion of ≥80%. In addition, the ER/IR ratio for the adjusted 193 means of AUC 0-8 was 120.09% with the 90% CI of 74.92%-192.51%, and for AUC 0-24 , the 194 ER/IR ratio for the adjusted means was 145.76% with the 90% CI of 93.74-226.64% (Table 2) . 
Safety assessment 203
There were no serious AEs. All AEs were mild or moderate in severity and all resolved by the end of 204 the study. In the IR group, five out of 19 subjects reported 5 treatment-emergent AEs: treatment 205 failure (2), anorexia (1), diarrhea (1) and vomiting (1). Among them, treatment failure and anorexia 206
were assessed as treatment-related by the investigator. In the ER group, four out of 19 subjects 207 reported 4 treatment-emergent AEs: nausea (1) and vomiting (3). Among them, one vomiting event 208
was assessed as treatment-related by the investigator. 209
The most commonly reported AE was vomiting (4 events). The vomiting event in the ER group, 210 which was assessed as treatment related, led to the discontinuation from the study. This event started 211 approximately 5 minutes after dosing and resolved approximately 19 hours after dosing, which was 212 assessed as mild in severity. The other two vomiting events in subjects from the ER group occurred at 213 a later time point with a very short duration: 9 and 35 hours after dosing, respectively. The vomiting in 214 the subject from the IR group also occurred at a later time point with a very short duration: 16 hours 215 after dosing. All the three vomiting events were attributed to disease under study. It is thought that 216 nausea and vomiting occur shortly after oral dosing of macrolides including azithromycin are 217 primarily local in origin and possibly due to the drug's action on the motilin receptors in the upper GI 218 tract (12, 14) . treatments was pre-defined as maintaining at least a lower 90% CI boundary of 80% to 245 demonstrate that the ER formulation is similar to or greater than the IR formulation, which was 246 consistent with the industry accepted lower boundary of bioequivalence range (80 -125%). The 247 ER/IR AUC 0-72 ratio for the adjusted means (90% CI) was 157.98% (98.87%, 252.44%), which 248 met the pre-defined criterion, thus the exposure from a 60 mg/kg ER dose was considered similar 249 to or greater than that from a 30 mg/kg IR dose. 250
Although the concentrations of ER during the first 3 hours were lower than those of IR, the 251 exposures over the first 8 hours (AUC 0-8 ) were comparable between these two treatments (Table  252 2). By 24 hours after dosing, the exposure (AUC 0-24 ) of ER treatment was similar or higher than 253 that of IR treatment (Table 2) . It indicated that slight delay in drug release of the ER formulation 254 has minimal impact on the total azithromycin exposure during the early state of treatment. 255
The azithromycin pharmacokinetic profiles in 7 subjects had a double peak: 3 from the ER group and 256 4 from the IR group. The reason of the double peaks is unknown. It was also observed from other 257 azithromycin pharmacokinetic studies (data on file). 258
Azithromycin was safe and well tolerated following single dose administration of either 259 formulation (60 mg/kg ER or 30 mg/kg IR) in children with AOM. Due to the small sample size, 260
comparisons cannot be made between the ER and IR formulations regarding safety. 261
The observed clinical cure rates for the 2 treatments appeared to be similar as all 18 completed 262 AOM subjects had clinical response assessed as cure in the ER group compared to 16 out of 18 263 completed subjects in the IR group. It is noted that this study was not designed to demonstrate 264 on July 7, 2017 by guest http://aac.asm.org/ Downloaded from clinical non-inferiority between these two treatments and other antibiotic therapy was permitted 265 during the study if clinically indicated. 266
Previously, the efficacy and safety of the 60 mg/kg azithromycin ER single dose regimen in 267 children with AOM had been evaluated in a randomized, double-blinded, double-dummy study 268 in comparison with a 10-day regimen of high dose amoxicillin-clavulanate (90/6.4 mg/kg/day, 269 given in divided doses q12h), particularly in children with or at risk for recurrent middle ear 270 infection (4). In the bacteriologic eligible population (clinically eligible subjects with a key 271 AOM pathogen isolated at baseline), the cure rates for azithromycin ER arm (n = 258) and 272 amox/clav arm (n = 239) were 80.2% and 84.5% respectively; an age-adjusted difference was -273 3.9% with 95% CI (-10.4%, 2.6%). Unfortunately, the lower boundary of the 95% CI (-10.4%) 274 marginally missed the study-defined non-inferiority criterion of -10%. Vomiting on day 1 had a 275 greater impact on the efficacy rate in the bacteriologic eligible population for azithromycin ER-276 treated subjects than for amox/clav-treated subjects. Specifically, 4 subjects in the azithromycin 277 ER arm vomited within 30 minutes of dosing on day 1 and were withdrawn from the study, in 278 comparison with 2 subjects in the amox/clav arm, and these subjects were assessed as clinical 279 failures at the TOC visit. In the bacteriologic per protocol population (bacteriologic eligible 280 subjects with a TOC visit), the cure rates for azithromycin ER arm (n = 239) and amox/clav arm 281 (n = 217) were 85.8% and 89.9%, respectively; the age-adjusted difference was -3.4% with 95% 282 CI (-9.1%, 2.4%). The most common treatment-related AE for ER group were vomiting (10.7%), 283 diarrhea and loose stools (9.3% each), and rash (5.1%). The most common treatment-related AEs 284 for amox/clav group were diarrhea (17.7%), loose stools (12.8%), vomiting (8.2%), rash (7.7%), 285 and dermatitis (5.1%). The AE profile of azithromycin ER was favorable compared with 286 amox/clav, particularly with respect to diarrhea. Although azithromycin ER subjects had a higher 287 on July 7, 2017 by guest http://aac.asm.org/ Downloaded from incidence of immediate vomiting after dosing, the incidence of longer-term vomiting was higher 288 for amox/clav subjects. 289
Subsequently, more effort was made to address the tolerability issue (early vomiting) with 290 azithromyicn ER. It has been demonstrated that this could be effectively managed by using a 291 more dilute (less viscous) concentration (27 mg/mL vs. the original 60 mg/mL suspension) and a 292 standardized dosing technique (3). The more dilute suspension (27 mg/mL) of the azithromycin 293 ER formulation was used in this study. 294
In summary, this study demonstrated that the 60 mg/kg azithromycin ER single dose provides similar 295 or greater systemic exposure in children with AOM compared with the 30 mg/kg azithromycin IR 296 single dose. 297
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